复星医药：宣布将口服 GLP-1 授权予辉瑞，意外利好

10 December 2025 | 7:41AM HKT Equity Research Fosun Pharma (2196.HK): Announces agreement to license out oral GLP-1 to Pfi zer; a positive surprise One more GLP-1 deal: Fosun Pharma announced that its subsidiary, Yao Pharma, has licensed out the global rights of YP05002, a phase 1 oral GLP-1, to Pfizer (PFE, covered by Asad Haider) for an 1) upfront payment of US$150mn; 2) potential development milestone payments of up to US$350mn based on clinical and commercial progress in US/EU5/Japan/China; and 3) poten ...